Redhill Biopharma EBIT

The latest EBIT for RDHL is $-8.2M as of June 2025. That compares with $-20M in the prior-year period — up 60.1% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Redhill Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, RDHL's EBIT moved from $-20M to $-8.2M — a 60.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Redhill Biopharma's operating scale or balance-sheet position.

Against Healthcare companies, RDHL currently prints $-8.2M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Redhill Biopharma's growth, margins, and balance sheet.

A EBIT figure of $-8.2M for RDHL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting RDHL's EBIT ($-8.2M), review year-over-year change from $-20M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.